Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Rizatriptan Benzoate Orally Disintegrating Tablets (ODT) 5mg and 10mg. The Abbreviated New Drug Application (ANDA) 203062 is ready for launch.
Rizatriptan Benzoate ODT 5mg and 10mg are the generic equivalent of Merck & Co. Inc’s Maxalt-MLT ODT 5mg and 10mg respectively and indicated for the acute treatment of migraine in adults and in pediatric patients 6 to 17 years of age.
The annual sale of the product is about $271 million for 12 months ending April 2013 as per IMS. The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India.
The company, now has a total of 192 ANDA approvals (164 Final approvals including 4 from Aurolife Pharma LLC and 28 Tentative approvals) from USFDA.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: